by According to a research report “Cancer Biopsy Market (By Product: Instruments, Kits and Consumables, Services; By Type: Tissue Biopsies, Liquid Biopsies, Others; By Application: Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030″ published by Precedence Research.
The cancer biopsy market size is projected to touch USD 28.36 billion in 2022 and is forecasted to reach USD 66.1 billion by 2030; it is expected to grow at a CAGR of 17.6 % from 2021 to 2030.
The study provides an analysis of the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2021 is considered as the base year.
The most common way for doctors to diagnose cancer is through a biopsy. Other tests can indicate the presence of cancer, but only a biopsy can confirm the diagnosis. A biopsy is a procedure in which a doctor takes a small piece of tissue for examination under a microscope. However, obtaining a tissue sample may necessitate surgery or another operation. The sort of biopsy one undergoes is determined by the location of the suspected tumor. The rising incidence and prevalence of cancer, as well as the growing desire for non-invasive treatment approaches, are driving the growth of the cancer biopsy market during the forecast period.
Get a Free Sample Copy of this Report with Global Industry Analysis @ https://www.precedenceresearch.com/sample/1514
The results of biopsy can be used by doctors to decide a patient’s treatment plan. These benefits are bolstering vendors’ efforts to provide patients with lung cancer with a customized treatment plan. The personalized medicine ensures that medications are targeted and actionable. During the forecast period, one of the important aspects likely to have favorable impact on the cancer biopsy market is the use of liquid biopsy for personalized treatment. However, due to tissue biopsy constraints, cancer misdiagnosis, delayed diagnosis, and insufficient tumor sampling are all common.
Table of Contents
Scope of the Cancer Biopsy Market
| Report Coverage | Details |
| Market Size | US$ 66.1 Billion by 2030 |
| Growth Rate | CAGR of 17.6% from 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Product, Application, Region |
Market Dynamics
Drivers
Increasing significance of companion diagnostics
The companion diagnostics are tests that help doctors make treatment decisions for patients based on their response to therapy. The foundation of companion diagnostics with therapeutic goods has the potential to radically modify the drug development process and commercialize drug candidates by swiftly and cost-effectively delivering safer medications with improved therapeutic efficacy. The market for companion diagnostics has a lot of growth opportunities because of the rising need for high priced specialist therapies and safer medications. Thus, the increasing significance of companion diagnosis is propelling the growth of the global cancer biopsy market during the forecast period.
Restraints
Unclear reimbursement scenarios
The process of paying for expensive molecular testing, as well as the expertise of the various professionals needed to interpret test results and establish treatment programs, is inefficient and complicated. This is especially true in the case of emerging technologies with bigger price tags, such as liquid biopsy. Thus, this factor is restricting the market growth.
Opportunities
Rising prevalence of various cancers
There has been a huge increase in the number of people diagnosed with cancer around the world. The environmental causes, infectious agents such as Hepatitis B and C, cigarette consumption, and lifestyle changes are all contributing to the increased cancer prevalence. The reduced cost, therapy monitoring, early prognosis, detection of tumor heterogeneity, patient comfort, and acquired drug resistance are all advantages of biopsy over standard cancer diagnostics approaches. As a result, the rising prevalence of various types of cancers is creating lucrative opportunities for the growth of the global cancer biopsy market during the forecast period.
Challenges
Limitations to the biopsy process
The amount of tissue retrieved from a needle biopsy may not be sufficient in some situations, and the biopsy may need to be repeated. Less invasive breast biopsy methods may occasionally fail to detect lesions or determine the extent of illness. The surgical biopsy is frequently required if the diagnosis remains questionable following a technically effective treatment. Thus, the limitations of the biopsy process are creating obstacles for the growth of the cancer biopsy market.
Report Highlights
- Based on the type, the tissue biopsy segment dominated the global cancer biopsy market in 2020 with highest market share. Tissue biopsies are commonly used to diagnose cancer, but they can also be used to diagnosis infections, autoimmune illnesses, and inflammatory diseases.
- Kits and consumables accounted for the biggest revenue share by product in 2020. Due to the considerable movement from tumor to liquid biopsy, the use of kits and consumables is projected to expand at rapid pace.
- Breast cancer dominated the global cancer biopsy market in terms of application in 2020, and it is expected to continue to do so throughout the forecast period. A reference standard for the examination of patients with a suspicious breast lesion is an open surgical biopsy.
Regional Snapshot
North America is the largest segment for cancer biopsy market in terms of region. The wide availability of technologically advanced instruments, highly developed healthcare systems in the U.S. and Canada, and the existence of numerous prominent national clinical laboratories account for the considerable proportion of this regional segment.
Asia-Pacific region is the fastest growing region in the cancer biopsy market. The regional expansion will be aided by increased cancer incidence, faster adoption of advanced methods, and highly upgraded infrastructure. The segment will also see exceptional development potential as the need for non-invasive illness detection grows, and the key market players continue to launch new products with a strong focus on research and development.
Read Also: Ambulance Services Market Size to Touch US$ 95.1 Bn by 2030
Some of the prominent players in the global cancer biopsy market include:
- Myriad Genetics Inc.
- Guardant Health Inc.
- Exact Sciences Corporation
- Bio-Rad Laboratories Inc.
- Agena Bioscience Inc.
- Personal Genome Diagnostics Inc.
- Exosome Diagnostics Inc.
- ANGLE Plc.
- F. Hoffmann-La Roche Ltd.
Segments Covered in the Report
By Product
- Instruments
- Kits and Consumables
- Services
By Type
- Tissue Biopsies
- Fine Needle Aspiration (FNA)
- Core Needle Biopsy (CNB)
- Needle Biopsies
- Surgical Biopsies
- Liquid Biopsies
- Others
By Application
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Why should you invest in this report?
If you are aiming to enter the global cancer biopsy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cancer biopsy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Biopsy Market
5.1. COVID-19 Landscape: Cancer Biopsy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Biopsy Market, By Product
8.1. Cancer Biopsy Market, by Product Type, 2021-2030
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Kits and Consumables
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Biopsy Market, By Application
9.1. Cancer Biopsy Market, by Application, 2021-2030
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Cervical Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Lung Cancer
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Skin Cancer
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Blood Cancer
9.1.7.1. Market Revenue and Forecast (2019-2030)
9.1.8. Kidney Cancer
9.1.8.1. Market Revenue and Forecast (2019-2030)
9.1.9. Liver Cancer
9.1.9.1. Market Revenue and Forecast (2019-2030)
9.1.10. Pancreatic Cancer
9.1.10.1. Market Revenue and Forecast (2019-2030)
9.1.11. Ovarian Cancer
9.1.11.1. Market Revenue and Forecast (2019-2030)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Biopsy Market, By Type
10.1. Cancer Biopsy Market, by Type, 2021-2030
10.1.1. Tissue Biopsies (Fine Needle Aspiration (FNA), Core Needle Biopsy (CNB))
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Liquid Biopsies
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Cancer Biopsy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.3. Market Revenue and Forecast, by Type (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Type (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Type (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.3. Market Revenue and Forecast, by Type (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Type (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Type (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Type (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Type (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.3. Market Revenue and Forecast, by Type (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Type (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Type (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Type (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Type (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.3. Market Revenue and Forecast, by Type (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Type (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Type (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Type (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Type (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.3. Market Revenue and Forecast, by Type (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Type (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Type (2019-2030)
Chapter 12. Company Profiles
12.1. Myriad Genetics Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Guardant Health Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Exact Sciences Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bio-Rad Laboratories Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Agena Bioscience Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Personal Genome Diagnostics Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Exosome Diagnostics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. ANGLE Plc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. F. Hoffmann-La Roche Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1514
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
